The firm expects to receive net proceeds of up to $51.4 million at a price range of $13 to $15 per share for its IPO.
The company issued more than 8.6 million shares at €11.50 per share in its IPO. Its shares list on Euronext Brussels under ticker symbol "BCART."
The microbial genetics analysis firm said in an SEC document that it plans to offer between 2.5 million units of stock and warrants at between $5.50 and $6.50 per unit.
The company plans to offer 3.75 million shares of its stock at $8 to $10 per share, and anticipates listing on the Nasdaq under ticker symbol "OPGN."
The gene editing company priced its initial public offering of 5.5 million American Depositary Shares with expectations of going public on the Nasdaq.
In an SEC document, the company said that current terms were not attractive enough for it to continue with a public offering.
The company was founded in 2002 with a whole-genome mapping technology and more recently moved into the microbial genetics space.
The firm said that it plans to list its stock on the Nasdaq under ticker symbol "RAIN" and added that its 2014 revenues were up 78 percent year over year to $30.6 million.
Despite an initial focus on cardiovascular disease, Miragen has moved programs in hematological cancer and fibrosis to the front of its pipeline.
The Australian company has also inked a deal to launch its proteomics-based kidney disease test in China.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.